Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV

A novel prediction model to evaluate the probability of CD4/CD8 ratio restoration in HIV-infected individuals

(2022) Bei Li et al.   AIDS

Aging, trends in CD4/CD8 ratio and clinical outcomes with persistent HIV suppression in the HIV outpatient study (HOPS)

(2022) Richard M. Novak et al.   AIDS

Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression

(2022) Samukelisiwe Ngcobo et al.   Scientific Reports

Moderate to Intense Physical Activity Is Associated With Improved Clinical, CD4/CD8 Ratio, and Immune Activation Status in HIV-Infected Patients on ART

(2021) Enrique Bernal et al.   Open Forum Infectious Diseases

Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort

(2021) Alessandro Lazzaro et al.   Diagnostics

Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

(2020) Sergio Serrano-Villar et al.   Lancet HIV

The effect of protease inhibitor‐based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART‐naïve patients with HIV‐infection

(2020) MI Figueroa et al.   HIV MEDICINE

CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment

(2019) Marta Monsalvo et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Does simplification to dolutegravir-based dual regimens impact on the CD4+/CD8+ T-cell ratio?

(2018) Amedeo F. Capetti et al.   AIDS

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

(2018) Cristina Mussini et al.   BMC Medicine

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy

(2016) Jessica L. Castilho et al.   AIDS

The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation

(2015) Nikolas Itaru Wada et al.   AIDS

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study

(2015) Cristina Mussini et al.   Lancet HIV

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality

(2014) Sergio Serrano-Villar et al.   PLoS Pathogens